
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Catheter Precision Inc. (VTAK)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VTAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $2
1 Year Target Price $2
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.75% | Avg. Invested days 12 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.59M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -0.28 | 52 Weeks Range 2.49 - 47.31 | Updated Date 08/15/2025 |
52 Weeks Range 2.49 - 47.31 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 33.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-08-11 | When - | Estimate 0.02 | Actual -0.38 |
Profitability
Profit Margin - | Operating Margin (TTM) -1338.68% |
Management Effectiveness
Return on Assets (TTM) -29.44% | Return on Equity (TTM) -184.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70083530 | Price to Sales(TTM) 5.98 |
Enterprise Value 70083530 | Price to Sales(TTM) 5.98 | ||
Enterprise Value to Revenue 116.81 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 23300000 | Shares Floating 1087840 |
Shares Outstanding 23300000 | Shares Floating 1087840 | ||
Percent Insiders 4.31 | Percent Institutions 1.78 |
Upturn AI SWOT
Catheter Precision Inc.
Company Overview
History and Background
Catheter Precision, Inc. was founded in 2011. The company focuses on precision electrophysiology for arrhythmia management. Their key focus is on developing and commercializing innovative technologies for mapping and ablation of cardiac arrhythmias.
Core Business Areas
- Mapping and Ablation: Development and commercialization of systems used for mapping and ablation of cardiac arrhythmias. This includes products that aid in visualizing and targeting the areas in the heart causing irregular heartbeats.
Leadership and Structure
David Jenkins serves as the Chief Executive Officer. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- VIVO System: A 3D cardiac mapping system designed to visualize the location and orientation of catheters in the heart during electrophysiological procedures. This helps physicians guide the catheter more accurately and efficiently. No significant market share data available publicly. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX).
- LOCAWI System: A catheter tip location system designed to help identify the optimal location to ablate tissue in the heart that causes arrhythmia. No significant market share data available publicly. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The electrophysiology market is experiencing growth driven by the increasing prevalence of cardiac arrhythmias such as atrial fibrillation. Advancements in technology are driving innovation and adoption of new mapping and ablation techniques.
Positioning
Catheter Precision focuses on developing and marketing innovative mapping and ablation technologies targeting specific niches within the electrophysiology market. Catheter Precision does not appear to hold a large market share.
Total Addressable Market (TAM)
The global electrophysiology market is estimated to be billions of dollars. Catheter Precision is positioned to capture a portion of this TAM through its innovative technologies, however, it is unclear what specific percentage of the TAM they can achieve.
Upturn SWOT Analysis
Strengths
- Innovative mapping and ablation technologies
- Focus on precision and accuracy
- Experienced leadership team
Weaknesses
- Limited market share
- Dependence on key products
- Limited financial resources relative to larger competitors
- Stock Delisting from NYSE American Exchange
Opportunities
- Expanding market for electrophysiology procedures
- Partnerships with larger medical device companies
- Acquisition by a larger player in the industry
- FDA Approval of new products.
Threats
- Competition from larger companies with more resources
- Technological obsolescence
- Regulatory hurdles
- Reimbursement pressures
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Catheter Precision faces intense competition from larger, more established companies. Its advantage lies in its innovative technologies. However, its ability to compete effectively depends on securing adequate funding and achieving broader market adoption.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited by market penetration.
Future Projections: Future projections are uncertain and dependent on successful product launches and market adoption.
Recent Initiatives: Recent initiatives focus on commercialization and market expansion efforts.
Summary
Catheter Precision is a small company with innovative technology in the electrophysiology market, but faces significant challenges. It has limited market share and competes against much larger, better-funded companies. The company needs to increase its market presence, secure additional funding, and continue to innovate to remain competitive. The recent delisting also creates concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party industry reports
- Various News Sources
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and financial data is based on limited available information and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catheter Precision Inc.
Exchange NYSE MKT | Headquaters Fort Mill, SC, United States | ||
IPO Launch date 2018-09-27 | CEO, Chief Commercial Officer & Executive Chairman Mr. David A. Jenkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 22 | |
Full time employees 22 |
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.